Mergers and Acquisitions

Earlier this year, Axol Bioscience announced the acquisition of Phenocell SAS with the goal of expanding cell models and services to include dermatology and ophthalmology.

Axol Biosciences specialises in induced pluripotent stem cell (iPSC)-derived cell models in the fields of neuroscience, pain and touch, and extends to cardiovascular drug discovery. With additional expertise from Phenocell, including its human iPSC-derived sebocy tes and retinal pigment epithelium (PRE), these models will expand to include skin and human retinal iPSC models.

Brigitte Onteniente, CEO and founder of Phenocell commented, “As part of Axol Bioscience we look forward to working with Liam and the team to develop a larger range of models, to serve a wider market.”

Axol Biosciences is expected to announce projects that will utilise the combined expertise in the coming months. The company stated that it is ‘excited ’ to join forces in order to work together to achieve Axol’s commitment to delivering better human disease models to aid biomedical research.

CEO of Axol Bioscience Liam Taylor stated, “This acquisition enables us to extend our product portfolio into ophthalmology and dermatology and offer iPSC-based skin and vision loss models. We are delighted to welcome Phenocell to the Axol Bioscience family and look forward to building an even wider range of advanced in vitro models of human disease, combining our shared values and passion to accelerate drug discovery.”